Vitamin E (natural d-alpha vs synthetic dl-alpha tocopherol) trials recruiting now
10 registrations that name vitamin E as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 10 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 10 registrations
RecruitingNCT07331103
RESOLving INflammation Through Diet for Health (RESOLVIN)
No phase
Mario Negri Institute for Pharmacological Research
About 324 people
Started Nov 26, 2025
In plain words A study of vitamin E in people 55 and older, run by Mario Negri Institute for Pharmacological Research. It plans to enroll about 324 people at 9 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 55 and older. Conditions: Cardiovascular (CV) Risk; Inflammation; Omega 3.
Participants are subjects >55 y old from both sexes (>=40% women) with moderate to high cardiovascular risk (ANNEX 1: SCORE2, SCORE2-OP and SCORE2-Diabetes assessment).
The exclusion criteria are on the listing.
What it tests, as registered
Fish Oil; Camelina oil; Vitamin E
Registered summary
Hyperlipidemia is the main driver of atherosclerotic cardiovascular disease (ASCVD), both through direct effects and as trigger of the chronic inflammation behind a cardiovascular health-to-disease transition. While lipid-lowering is an effective way to reduce the ASCVD risk, the residual risk remains high. In addition, a substantial proportion of ASCVD events occur in the absence of overt hyperlipidemia. Several lines of evidence ranging from experimental models to population studies and interventional clinical trials support chronic inflammation as the causal residual risk of CVD. The full summary is on the listing.
Where, as registered
No US site; Italy (9).
RecruitingNCT07303803
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
Phase 2
Shanghai Jiao Tong University School of Medicine
About 300 people
Started Jan 1, 2026
In plain words A Phase 2 study of vitamin E in people 18 to 75, run by Shanghai Jiao Tong University School of Medicine. It plans to enroll about 300 people at 17 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: MASH - Metabolic Dysfunction-Associated Steatohepatitis; T2DM (Type 2 Diabetes Mellitus).
Men and women aged at least 18 years and under 75 years (inclusive) at the time of obtaining consent.
Participants must be diagnosed as T2DM and HbA1c ≤ 9.5% at time of screening.
Participants must take Fibroscan examination with the result of CAP ≥ 238 dB/m and LSM>8.5 kPa.
Diagnosis of MASH by liver biopsy, with NAFLD Activity Score (NAS) ≥4 with ≥1 point for each component, and fibrosis stage 1b or more over according to the NASH Clinical Research Network (CRN) scoring system.
3 more inclusion criteria and the exclusion criteria are on the listing.
This trial aims to evaluate the efficacy and safety of chiglitazar as a combination therapy for patients with MASH and T2DM.
Where, as registered
No US site; China (17).
RecruitingNCT07877948
Comparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients and Its Effect on Wound Healing
No phase
BREGO Life Sciences
About 100 people
Started Jul 22, 2025
In plain words A study of vitamin E in people 18 and older, run by BREGO Life Sciences. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Diabetic Foot Ulcer (DFU); Diabetic Symmetrical Polyneuropathy.
Aged 18 years and above
Diagnosed with Type 2 Diabetes Mellitus
HbA1C of <8%
Symptoms of DSPN attributed by diabetes mellitus using Toronto Clinical Neuropathy Scoring (TCNS)
12 more inclusion criteria and the exclusion criteria are on the listing.
Diabetic symmetrical polyneuropathy (DSPN) is a common complication of diabetes that affects the nerves, especially in the legs and feet. It can cause pain, numbness, tingling, weakness, and loss of sensation. These problems can affect daily activities and quality of life. Loss of sensation can also increase the risk of foot wounds and problems with wound healing. This study is comparing two treatments in people with type 2 diabetes and DSPN. The full summary is on the listing.
Where, as registered
No US site; Malaysia (1).
RecruitingNCT07312123
A Study to See Whether Taking a Mix of Vitamins Can Help Adults Recover Better After Surgery for Carpal Tunnel Syndrome
No phase
Hospital Universiti Sains Malaysia
About 84 people
Started Dec 8, 2025
In plain words A study of vitamin E in people 18 and older, run by Hospital Universiti Sains Malaysia. It plans to enroll about 84 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Carpal Tunnel Syndrome.
Age more than 18 years old
Subjects with symptoms and physical examination of CTS
Patients with CTS going for CT release
The exclusion criteria are on the listing.
What it tests, as registered
Alpha-Lipoic Acid, Vitamin E, and Vitamin B Complex; Combination Vitamin B1,B6,B12
Registered summary
Carpal Tunnel Syndrome (CTS) is a common condition that causes numbness, tingling, pain, and weakness in the hand due to compression of the median nerve at the wrist. It can affect daily activities, work performance, and quality of life. While surgery is effective in severe cases, many patients with mild to moderate CTS are initially treated with non-surgical options such as splinting and medications. However, the effectiveness of oral supplements for CTS remains uncertain. The full summary is on the listing.
Where, as registered
No US site; Malaysia (1).
RecruitingNCT06321991
Nodular Shrinking in Dupuytren Disease
Phase 2
Universitaire Ziekenhuizen KU Leuven
About 80 people
Started Feb 15, 2024
In plain words A Phase 2 study of vitamin E in people 18 and older, run by Universitaire Ziekenhuizen KU Leuven. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Dupuytren's Disease.
The participant or his/her legally authorized representative voluntary signed the informed consent prior to the first assessment.
Participants are ≥ 18 years and diagnosed with primary Dupuytren disease.
Included patients have a stage 0 DD (nodule of at least 5 mm in the involved hand without contracture).
The participant has well distinguished noduli that are clearly visible on US (ultrasound)
The exclusion criteria are on the listing.
What it tests, as registered
Vitamin E-creme (Remederm®) vs Vaseline (Placebo); Ultrasound measurement
Registered summary
Dupuytren disease (DD) is a common hand disorder with disabling finger contractures that may require surgery to restore function. In the early stages of the disease, the nodules (Tubiana stage 0) are usually painless, but a reason for concern to many patients. Not rarely, lifestyle measures and even risky treatment options as radiotherapy are advised, yet no therapy to prevent disease evolution has a solid proven effect. Furthermore, reliable non-invasive measurement of early stage DD is not validated. The full summary is on the listing.
Where, as registered
No US site; Belgium (1).
RecruitingNCT06915701
"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"
Phase 2 and 3
University of Guadalajara
About 46 people
Started Feb 6, 2026
In plain words A Phase 2 and 3 study of vitamin E in female participants 18 and older, run by University of Guadalajara. It plans to enroll about 46 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Rheumatoid Arthritis.
Female sex
RA classification (ACR/EULAR 2010)
Early RA 2 years
Treatment with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations)
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Will take vitamin E 800mg/day; Will take 200mg/day magnesium oxide placebo.
Registered summary
The objective of this clinical trial is to determine whether α-tocopherol (vitamin E) supplementation decreases inflammation and clinical activity in patients with rheumatoid arthritis (RA).The main questions to be answered are: * Is supplementation with vitamin E (α-tocopherol) for one month associated with decreased clinical activity and inflammation in patients with RA? Researchers will compare α-tocopherol with a placebo (a look-alike substance containing no active ingredient) to see if α-tocopherol effectively reduces inflammation and clinical activity in patients with rheumatoid… The full summary is on the listing.
Where, as registered
No US site; Mexico (2).
RecruitingNCT05771181
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Phase 2
Fudan University
About 25 people
Started Mar 1, 2023
In plain words A Phase 2 study of vitamin E in people 18 and older, run by Fudan University. It plans to enroll about 25 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Colorectal Cancer; Microsatellite Stable Colorectal Carcinoma.
Age ≥18 years old, both sexes;
Patients with histologically or cytologically confirmed unresectable and metastatic CRC;
Recist1.1-defined disease progression or intolerance to prior standard therapy during or after standard therapy.
Before enrollment, the tumor tissue was pMMR by immunohistochemistry, or MSS or MSI-L by PCR or NGS;
15 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Vitamin E; Fruquintinib; Tislelizumab
Registered summary
The goal of this clinical trial is to learn about efficacy of Vitamin E in combination with Fuquinitinib and Tirelizumab in patients with microsatellite stabilized mCRC who have failed standard therapy. The main question is to explore the survival time, safety and tolerability of the treatment. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07668284
COQ10 and Vitamin E for Off-Target Radiation Toxicity
Phase 1 and 2
University of Nebraska
About 200 people
Starts Dec 1, 2026 (estimated)
In plain words A Phase 1 and 2 study of vitamin E in people 19 and older, run by University of Nebraska. It plans to enroll about 200 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 19 and older. Conditions: Prostate Cancer; Uterine Cancer; Cervical Cancer; Anal Cancer.
Pathologically confirmed post-prostatectomy prostate, uterine (endometrial and cervical), or anal cancer.
Scheduled for curative-intent, multi-fraction (at least 15 fractions) external-beam radiotherapy +/- chemotherapy at the study site which does not involve re-irradiation to the same field.
Age ≥ 19 years at the time of consent.
Eastern Cooperative Oncology Group Performance Status ≤ 2.
15 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Coenzyme Q10 Cap/Tab; Vitamin E Cap/Tab
Registered summary
The goal of this supportive care study is to learn if high-dose Vitamin E and CoQ10 in combination can reduce the negative sub-acute and chronic side effects of radiation to the pelvis in adults treated for prostate, uterine, cervical, or anal cancer. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT06926712
The Effect of Vitamin E Supplementation on Hospital Stay Duration in Non-cyanotic Heart Disease Children With Lower Respiratory Tract Infections
Phase 4
Assiut University
About 260 people
Starts Jun 2025 (estimated)
In plain words A Phase 4 study of vitamin E in people 2 months to 5, run by Assiut University. It plans to enroll about 260 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 2 months to 5. Conditions: Respiratory Disease.
Pediatric patients are diagnosed with non-cyanotic heart disease associated with severe lower respiratory tract infection. ⁃ The patients are aged 2 months to 5 years of both sexes.
The exclusion criteria are on the listing.
What it tests, as registered
Vitamin E
Registered summary
Congenital heart disease can lead to serious health issues, particularly an increased risk of infections, specifically respiratory infections. Lower respiratory tract infections are the fifth leading cause of death globally. Also considered a significant cause of morbidity and mortality among children with congenital heart disease. In Egypt, it is estimated that 10% of deaths in children under the age of 5 years are probably caused by lower respiratory tract infections and other acute respiratory infections. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07863648
Vitamin E Versus Silymarin in Non Diabetic MASLD Patients
Phase 3
Kafrelsheikh University
About 120 people
Starts Oct 16, 2026 (estimated)
In plain words A Phase 3 study of vitamin E in people 18 to 65, run by Kafrelsheikh University. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Metabolic Dysfunction-Associated Steatoic Liver Disease.
Adults (18-65 y),
Diagnosed with MASLD (CAP ≥248 dB/m on FibroScan, ALT >40 IU/L),
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Vitamin E 800 IU/d; Silymarin 420 mg; Placebo
Registered summary
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), is a chronic liver condition marked by excessive fat buildup (steatosis) in liver cells, linked to at least one metabolic risk factor like obesity, type 2 diabetes, high blood lipids, or hypertension. Vitamin E serves as a recommended antioxidant therapy for select MASLD patients. It reduces liver inflammation markers such as ALT and AST, alongside benefits in steatosis and MASH resolution. The full summary is on the listing.